Panelists highlight that menin inhibitors represent a breakthrough in the treatment of KMT2A-rearranged AML by targeting the disease’s core epigenetic drivers, with early clinical trials like ...

The overall 5-year relative survival rate for AML is about 30%, but this number is an estimate based on a large group of people and does not predict individual outcomes. Younger people with AML tend ...

Treosulfan plus fludarabine is approved for alloHSCT in patients with AML or MDS aged 1 year and older. Clinical trial results showed improved overall survival with treosulfan compared to busulfan.

Mixed phenotype acute leukemia is when these two forms of leukemia combine. If you have too few normal white blood cells, you may get infections and fevers over and over. A high white blood cell count ...

UK-based biotech Charm Therapeutics has closed an oversubscribed Series B funding round worth $80m, which will support the progression of its acute myeloid leukaemia (AML) menin inhibitor into ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...